Lorvotuzumab mertansine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lorvotuzumab mertansine
Accession Number
DB12089
Description

Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
  • IMGN901

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lorvotuzumab mertansine.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Lorvotuzumab mertansine.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Lorvotuzumab mertansine.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Lorvotuzumab mertansine.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Lorvotuzumab mertansine.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lorvotuzumab mertansine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Lorvotuzumab mertansine.
AlectinibThe metabolism of Alectinib can be decreased when combined with Lorvotuzumab mertansine.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorvotuzumab mertansine.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Lorvotuzumab mertansine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
0IVD6ASY0W
CAS number
1008106-64-6

References

General References
Not Available
PubChem Substance
347911280
Wikipedia
Lorvotuzumab_mertansine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentPleuropulmonary Blastoma / Recurrent Malignant Peripheral Nerve Sheath Tumor / Recurrent Neuroblastoma / Recurrent Rhabdomyosarcoma / Recurrent Synovial Sarcoma / Wilms' tumor1
2CompletedTreatmentLeukemias1
1CompletedTreatmentMultiple Myeloma (MM)2
1CompletedTreatmentNeuroendocrine Carcinoma of the Skin / Ovarian Cancer / Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentSmall Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [PubMed:11020135]

Drug created on October 20, 2016 15:19 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates